Core Insights - Dyne Therapeutics announced new preclinical data for DYNE-302, showing potential functional improvement in facioscapulohumeral muscular dystrophy (FSHD) [1][2] - The data will be presented at the 32nd Annual FSHD Society's International Research Congress in Amsterdam on June 12-13, 2025 [1][4] Company Overview - Dyne Therapeutics is focused on developing therapeutics for genetically driven neuromuscular diseases, leveraging its FORCE™ platform [6] - The company has a broad pipeline that includes clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as preclinical programs for FSHD and Pompe disease [6] Disease Background - FSHD is a rare, progressive genetic disease caused by a mutation in the DUX4 gene, leading to muscle loss and weakness [5] - An estimated 16,000 to 38,000 individuals in the U.S. and approximately 35,000 in Europe are affected by FSHD, with no approved therapies currently available [5] Research Findings - In a mouse model of severe FSHD, a single intravenous dose of DYNE-302 restored the ability to run on a treadmill, indicating potential reversal of muscle damage and inflammation [2][3] - DYNE-302 targets DUX4 mRNA to suppress its expression, aiming to address the underlying cause of muscle damage in FSHD [3] Presentation Details - The oral presentation on DYNE-302's effects will take place on June 13, 2025, at 12:00 p.m. CEST [4] - The presentation will be available on Dyne's website following the session [4]

Event Recognizes Bowman’s Journey from Local Firm to National Engineering PartnerRESTON, Va., June 05, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, will ring the Nasdaq Stock Market opening bell on June 9, 2025, commemorating its 30th anniversary. Founder and CEO, Gary Bowman, alongside members of the Company’s leadership team and employees, will participate in the ceremonial bell ringing at the Nasdaq MarketSite in Times ...

Core Points - Bread Financial Holdings, Inc. announced a cash tender offer for its 9.750% Senior Notes due 2029, with approximately $536,786,000 validly tendered by the Early Participation Date [1][3] - The company plans to accept up to $150,000,000 in aggregate principal amount of the Notes, resulting in a Total Consideration of $1,071.25 for each $1,000 principal amount of Notes accepted [1][5] - The Tender Offer includes an early participation amount of $50.00 per $1,000 principal amount of Notes for those who tendered by the Early Participation Date [3][5] Tender Offer Details - The total outstanding principal amount of the 9.750% Senior Notes is $900,000,000, with $536,786,000 tendered as of the Early Participation Date [2] - The expected total consideration for the accepted Notes includes the early participation amount and accrued interest [3][5] - The company anticipates settlement of the accepted Notes on June 9, 2025, subject to the conditions set forth in the Offer to Purchase [7] Proration and Acceptance - Due to the Tender Cap being exceeded, the company will accept Notes on a prorated basis, with an expected proration factor of approximately 77.538% for those tendered at the Clearing Premium [7] - Notes tendered at a Bid Price resulting in a Bid Premium exceeding the Clearing Premium will not be accepted [7] Dealer Managers - J.P. Morgan Securities LLC is the sole lead dealer manager for the tender offer, with several co-dealer managers assisting in the process [8]

Core Viewpoint - Cellebrite has announced its agreement to acquire Corellium for an enterprise value of $170 million in cash, enhancing its capabilities in digital investigations and security for smart devices [2][3] Company Overview - Cellebrite is a global leader in digital investigative solutions, focusing on enhancing digital investigations and intelligence gathering to accelerate justice [6] - Corellium specializes in Arm hypervisor virtualization, providing solutions for security and developer teams to build, test, and secure software for mobile, automotive, and IoT devices [7] Acquisition Details - The acquisition is valued at $170 million, with $20 million converted to equity at closing, and an additional $30 million contingent on performance milestones over the next two years [2] - The deal is expected to close in summer 2025, pending approval from the Committee on Foreign Investment in the United States [2] Strategic Benefits - The combination of Cellebrite and Corellium is expected to set a new standard for digital investigations and enhance the security of Arm-based devices across various applications [1] - Corellium's technology will broaden Cellebrite's Total Addressable Market (TAM) in both public and private sectors, enhancing its Digital Investigation Platform and mobile vulnerability research capabilities [1][2] Technological Advancements - The acquisition will enable accelerated identification of mobile vulnerabilities and exploits, and provide an industry-first ability to visualize and interact with virtual devices [4] - Corellium's virtualization platform will enhance DevSecOps efficiency across all Arm-based devices, facilitating the development of high-performance, secure mobile applications and IoT devices [4][1]

LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the “Company”) (Nasdaq: DGNX), a leading provider of Sustainability RegTech solutions, today announced the signing of a Memorandum of Understanding (“MOU”) for a cash and share acquisition of Resulticks, a globally recognized leader in real-time, AI-driven customer engagement and data management solutions. This strategic move will significantly enhance Diginex’s capabilities in advanced data management and artificial intelligence, furth ...

Core Insights - Draganfly Inc. successfully participated in the Global Drone Innovation and Defense Coalition Summit, showcasing its advanced drone solutions and systems [1][4] - The summit saw the expansion of the Drone Coalition from 17 to 20 member states and highlighted a collective investment of €4 billion towards enhancing drone capabilities [2] - Draganfly was recognized as a leading provider, demonstrating its modular and interchangeable FPV platform, and multiple tactical deployment drone systems [3] Company Highlights - Draganfly showcased its interoperable family of tactical drone platforms, including The Commander 3XL, The APEX, and the modular Flex FPV [3] - The company emphasized its commitment to innovation and mission adaptability, engaging with academic and research institutions for potential collaborations in military drone advancements [4] - Draganfly's ongoing support for Ukraine and its focus on field-driven innovation were highlighted during the summit [5] Industry Context - The summit attracted over 1,500 participants from 28 countries, indicating a strong interest in drone technology within the defense sector [2] - The collective investment of €4 billion reflects the growing importance and prioritization of drone capabilities among coalition member states [2]

Core Viewpoint - The Joint Corp. has announced a stock repurchase program of up to $5 million, reflecting the board's confidence in the company's long-term strategy and projected cash flow generation [1][2]. Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S. through The Joint Chiropractic network, with over 950 locations and more than 14 million patient visits annually [3]. - The company operates a retail healthcare business model that eliminates the need for insurance, making chiropractic care more accessible and affordable [3]. - The Joint Corp. has received multiple accolades, including being named "No. 1 in Chiropractic Services" by Entrepreneur and consistently ranking in Franchise Times' annual lists [3]. Business Structure - The Joint Corp. functions as both a franchisor and operator of clinics in various states, providing management services to affiliated chiropractic practices [4]. Stock Repurchase Program Details - The stock repurchase program is set to begin in August 2025 and will have a termination date of June 3, 2027. The program allows for repurchases through various means, subject to market conditions [2]. - The finance committee of the board will determine the timing, number, and amount of repurchases at its discretion [2].

Core Viewpoint - Ocugen, Inc. has signed a binding term sheet to negotiate a licensing agreement for exclusive rights to its gene therapy OCU400 in Korea, aimed at treating retinitis pigmentosa (RP) [1][4]. Group 1: Licensing Agreement Details - The licensing agreement will provide Ocugen with upfront fees and near-term development milestones totaling up to $11 million [2][8]. - Ocugen will receive sales milestones of $1 million for every $15 million in net sales in Korea, along with a royalty of 25% on net sales generated by its partner [2][8]. - The company will manufacture the commercial supply of OCU400 under a supply agreement [2]. Group 2: Market Opportunity - There are approximately 15,000 individuals in South Korea affected by RP, presenting a significant market opportunity for the partner to lead in gene therapy [3]. - The regional licensing strategy aligns with Ocugen's goal to partner with established companies to maximize patient reach while generating returns for shareholders [4]. Group 3: Development Timeline - Ocugen is advancing OCU400 through Phase 3 clinical development, with a target for filing a Biologics License Application by mid-2026 [5].

About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, t ...

TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) ("NexGold" or the "Company") is pleased to provide an update on its ongoing 25,000-metre diamond drill program initially announced on January 22, 2025 at the Company's Goldboro Project in Nova Scotia ("Goldboro"). The drill program is primarily designed to infill specific areas of the open pit Mineral Resource identified to improve geological and grade continuity and potentially upgrade certain areas of Inferred and I ...